Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
•
Dermatology
How would you manage a patient with severe Hurley Stage 3 active, draining, HS who is also currently requiring Rituxan for management of vasculitis?
Would you be comfortable combining a TNFi with Rituxan in this patient?
Related Questions
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
How do you approach the workup of clinically diagnosed cutaneous vasculitis in healthy young individuals without systemic symptoms?
What is your experience of using rituximab for GPA with renal involvement following a recent myocardial infarction?
How would you manage a patient with ANCA associated vasculitis who has recurrent flare including pulmonary hemorrhage, persistent MPO antibody positivity while on maintenance rituximab and avacopan regimen even after induction rituximab therapy?
How would you approach the work up of a patient with nasal septal perforation, a negative infectious workup, and negative ANCA titers?
Would you continue Rituximab infusions in a patient with GPA and renal involvement who has been in remission on Avacopan and Rituximab, but had PRES post Rituximab infusion?
How would you approach additional workup and management of a patient with active Crohn’s disease, who has multiple lung and brain nodules, with lung pathology demonstrating necrotizing granulomatous inflammation and brain biopsy with granulomatous inflammation and medium-large vessel vasculitis?
What is the recommended approach for systemic therapy in a patient with metastatic cutaneous squamous cell carcinoma with active autoimmune disease (dermatomyositis)?
What is your approach to maintenance treatment in a patient with Sjogren's who received rituximab for mononeuritis multiplex?
What is your approach to management of hyperlipidemia in patients taking JAK inhibitors?